Renal Function after Intravitreal Administration of Vascular Endothelial Growth Factor Inhibitors in Patients with Diabetes and Chronic Kidney Disease
In conclusion, intravitreal administration of vascular endothelial growth factor inhibitors is unlikely to be associated with a deterioration of renal function in patients with diabetes and chronic kidney disease.
This article is protected by copyright. All rights reserved.
Source: Journal of Diabetes Investigation - Category: Endocrinology Authors: Yusuke Kameda, Tetsuya Babazono, Yasuko Uchigata, Shigehiko Kitano Tags: Short Report Source Type: research
More News: Avastin | Chronic Kidney Disease | Diabetes | Endocrinology | Lucentis | Ranibizumab Injection | Study | Urology & Nephrology